Current Role of the CardioMEMS Device for Management of Patients with Heart Failure
- 119 Downloads
Purpose of Review
Heart failure (HF) remains a significant burden to our healthcare system and a leading cause of hospitalizations. Current reactive strategies to treat and manage HF have failed to reduce hospitalizations and improve survival. The CardioMEMS device has recently been demonstrated to improve quality of life in HF and reduce HF-related hospitalizations. Current HF management strategies are reviewed with a particular emphasis on the current role of the CardioMEMS device.
The CHAMPION trial is the only randomized trial looking at the CardioMEMS device. Patients managed with targeted pulmonary artery pressures resulted in 28% reduction in the primary end-point of HF-related hospitalization at 6 months (HR 0.72, 95% CI 0.60–0.85, p = 0.0002) and 37% reduction during the entire follow-up period, which averaged 15 months (HR 0.63, 95% CI 0.52–0.77, p < 0.0001). The prospective open-label post-approval study recently presented a 58% reduction in HF hospitalizations per patient year (HR 0.42, 95% CI 0.38–0.47, p < 0.0001).
Management of HF using the CardioMEMS device has been shown to reduce HF hospitalizations and improve quality of life regardless of ejection fraction. Patients best suited for this device are those with recurrent congestive symptoms despite optimal medical therapy.
KeywordsCardioMEMS Heart failure Pulmonary artery pressure Implantable hemodynamic monitor
Compliance with Ethical Standards
Conflict of Interest
Calvin C. Leung declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19. https://doi.org/10.1161/HHF.0b013e318291329a.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000–2010. NCHS data brief, no 108. Hyattsville, MD: National Center for Health Statistics. NCHS Data Brief. 2012;(108):1–8.Google Scholar
- 9.Yancy CW, Lopatin M, Stevenson LW, de Marco T, Fonarow GC, ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006 Jan 3;47(1):76–84.CrossRefGoogle Scholar
- 10.Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–16.CrossRefGoogle Scholar
- 11.Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015;8(4):741–8. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001957.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefPubMedGoogle Scholar
- 16.Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118(14):1433–41. https://doi.org/10.1161/CIRCULATIONAHA.108.783910.CrossRefPubMedGoogle Scholar
- 20.Abraham WT, Compton S, Haas G, Foreman B, Canby RC, Fishel R, et al. Intrathoracic impedance vs. daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest Heart Fail. 2011;17(2):51–5. https://doi.org/10.1111/j.1751-7133.2011.00220.x.CrossRefPubMedGoogle Scholar
- 22.Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Böhm M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation. 2011;123(17):1873–80. https://doi.org/10.1161/CIRCULATIONAHA.111.018473.CrossRefPubMedGoogle Scholar
- 24.Pufulete M, Maishman R, Dabner L, Higgins JPT, Rogers CA, Dayer M, et al. B-type natriuretic peptide-guided therapy for heart failure: a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. Syst Rev. 2018;7(1):112. https://doi.org/10.1186/s13643-018-0776-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–92. https://doi.org/10.1001/jama.2009.2.CrossRefPubMedGoogle Scholar
- 26.Desai AS. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. Circulation. 2013;127(4):509–16; discussion 516. https://doi.org/10.1161/CIRCULATIONAHA.112.120493.CrossRefPubMedGoogle Scholar
- 29.Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J. 2011;32(18):2266–73. https://doi.org/10.1093/eurheartj/ehr050.CrossRefPubMedGoogle Scholar
- 31.Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol. 2010;55(17):1803–10. https://doi.org/10.1016/j.jacc.2009.11.089.CrossRefPubMedGoogle Scholar
- 32.van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011;124(16):1719–26. https://doi.org/10.1161/CIRCULATIONAHA.111.043042.CrossRefPubMedGoogle Scholar
- 33.Perego GB, Oldani M, Pellegrini D, Brasca FMA, Malfatto G, Villani A, et al. Correlation between pulmonary artery pressure and thoracic impedance: insights from daily monitoring through an implanted device in chronic heart failure. Int J Cardiol. 2017;245:196–200. https://doi.org/10.1016/j.ijcard.2017.07.042.CrossRefPubMedGoogle Scholar
- 34.Abraham WT, Adamson PB, Costanzo MR, et al. Hemodynamic monitoring in advanced heart failure: results from the LAPTOP-HF trial. Late-Breaking Clinical Trials. Presented at HFSA 2016. Orlando, FL; J Card Fail. 2016;22(11): 940. DOI: https://doi.org/10.1016/j.cardfail.2016.09.012 CrossRefGoogle Scholar
- 36.Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51(11):1073–9. https://doi.org/10.1016/j.jacc.2007.10.061.CrossRefPubMedGoogle Scholar
- 40.Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935–44. https://doi.org/10.1161/CIRCHEARTFAILURE.113.001229.CrossRefPubMedGoogle Scholar
- 41.• Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016;387(10017):453–61. https://doi.org/10.1016/S0140-6736(15)00723-0 This is the only current randomized trial looking at the CardioMEMS device.CrossRefPubMedGoogle Scholar
- 45.Shavelle DM. Pulmonary artery pressure-guided therapy for ambulatory heart failure patients in clinical practice: 1-year outcomes from the CardioMEMS post-approval study. Presented at: ACC 2019. New Orleans, LA; 2019.Google Scholar
- 47.Ollendorf DA, Sandhu AT, Chapman R, et al. CardioMEMS™ HF System (St. Jude Medical) and sacubitril/valsartan (Entresto™, Novartis) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks. Institute for Clinical and Economic Review. https://icer-review.org/wp-content/uploads/2016/01/CHF_Final_Report_120115.pdf. Accessed 28 May 2019
- 49.Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2304–22.CrossRefGoogle Scholar
- 50.Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Liu Y, Mehra MR, et al. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J Am Heart Assoc. 2012;1(1):16–26. https://doi.org/10.1161/JAHA.111.000018.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Choi KH, Choi JO, Jeon ES, et al. Guideline-directed medical therapy for patients with heart failure with midrange ejection fraction: a patient-pooled analysis from the KorHF and KorAHF registries. J Am Heart Assoc. 2018;7(21). https://doi.org/10.1161/JAHA.118.
- 55.• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975 This is the first guideline to incorporate the use of CardioMEMS in the management of HF. CrossRefGoogle Scholar
- 56.Angermann CE, Assmus B, Anker SD, Brachmann J, Ertl G, Köhler F, et al. Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clin Res Cardiol. 2018;107(11):991–1002. https://doi.org/10.1007/s00392-018-1281-8.CrossRefPubMedGoogle Scholar